All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00070583" target="_blank" >RIV/00216224:14110/13:00070583 - isvavai.cz</a>

  • Alternative codes found

    RIV/61989592:15110/13:33143920 RIV/65269705:_____/13:#0002106

  • Result on the web

    <a href="http://dx.doi.org/10.1038/leu.2013.171" target="_blank" >http://dx.doi.org/10.1038/leu.2013.171</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1038/leu.2013.171" target="_blank" >10.1038/leu.2013.171</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib

  • Original language description

    The introduction of tyrosine kinase inhibitors (TKI) in the treatment of Philadelphia chromosome-positive (Ph_) chronic myeloid leukemia (CML) has revolutionized the outcome, but the prognosis of the disease is still based on prognostic systems that weredeveloped in the era of conventional chemotherapy and interferon (IFN)-alfa. A new prognostic score including only two variables, spleen size and basophils, was developed for the prediction of complete cytogenetic response (CCyR) and progression-free survival (PFS). The score was based on a large series of patients who were enrolled in prospective multicenter studies of first-line imatinib treatment. The prognostic value of the EUTOS (European Treatment and Outcome Study for CML) score has now been tested in an independent, multicenter, multinational series of 1288 patients who were treated first-line with imatinib outside prospective studies.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2013

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Leukemia

  • ISSN

    0887-6924

  • e-ISSN

  • Volume of the periodical

    27

  • Issue of the periodical within the volume

    10

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    7

  • Pages from-to

    2016-2022

  • UT code for WoS article

    000325642600008

  • EID of the result in the Scopus database